Valuation: Senzime AB

Market Cap 43Cr 4.37Cr 3.89Cr 3.6Cr 3.28Cr 6.19Cr 415.08Cr 6.29Cr 17Cr 216.61Cr 16Cr 16Cr 690.51Cr P/E 2026 *
-
P/E 2027 * -
Enterprise Value 43Cr 4.37Cr 3.89Cr 3.6Cr 3.28Cr 6.19Cr 415.08Cr 6.29Cr 17Cr 216.61Cr 16Cr 16Cr 690.51Cr EV / Sales 2026 *
3.39x
EV / Sales 2027 * 2.12x
Free-Float
40.74%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Senzime AB

1 day+2.80%
1 week-5.65%
Current month-0.18%
1 month-7.86%
3 months-29.90%
6 months-49.91%
Current year-48.98%
1 week 2.64
Extreme 2.635
2.9
1 month 2.35
Extreme 2.35
3.26
Current year 2.35
Extreme 2.35
6
1 year 2.35
Extreme 2.35
6.24
3 years 2.35
Extreme 2.35
9.6
5 years 2.35
Extreme 2.35
24.8
10 years 2.35
Extreme 2.35
28.5
Manager TitleAgeSince
Chief Executive Officer 53 03/05/2023
Director of Finance/CFO 56 01/01/2022
Chief Tech/Sci/R&D Officer 50 01/01/2023
Director TitleAgeSince
Chairman 53 03/05/2023
Director/Board Member 70 01/01/2016
Director/Board Member 63 05/03/2020
Date Insider Type Main position Quantity % Market Cap. Importance
28/09/26 Buy

Director

1,78,388 0.1135%
25/09/26 Buy

Chief Technology Officer

30,000 0.0191%
24/09/26 Buy

Chief Technology Officer

30,000 0.0191%
Change 5-day change 1-year change 3-year change Capi.($)
+2.80%-5.65%-53.07%-55.64% 4.37Cr
+0.20%+5.31%-17.82%+13.79% 18TCr
-0.73%+7.09%-0.31%+32.06% 12TCr
+0.49%+6.25%-20.20%+11.58% 11TCr
+3.83%+5.50%-44.18%-6.77% 7.98TCr
-0.14%+5.27%+6.74%+82.45% 6.51TCr
+2.79%+2.37%+15.93%+68.64% 5.43TCr
-1.04%+4.35%+3.50%-26.18% 5.22TCr
+2.41%+8.18%-12.08%+30.45% 4.41TCr
-1.90%+2.29%+29.72%+8.98% 3.25TCr
Average +0.95%+4.19%-9.18%+15.93% 7.39TCr
Weighted average by Cap. +0.62%+5.59%-9.70%+22.13%

Financials

2026 *2027 *
Net sales 13Cr 1.29Cr 1.15Cr 1.06Cr 96.66L 1.82Cr 122.38Cr 1.85Cr 5.01Cr 64Cr 4.84Cr 4.74Cr 203.58Cr 20Cr 2.06Cr 1.83Cr 1.7Cr 1.54Cr 2.91Cr 195.5Cr 2.96Cr 8Cr 102.02Cr 7.73Cr 7.57Cr 325.22Cr
Net income -6.89Cr -69.57L -61.84L -57.32L -52.15L -98.41L -66Cr -99.99L -2.7Cr -34Cr -2.61Cr -2.56Cr -109.84Cr -3.68Cr -37.16L -33.03L -30.61L -27.85L -52.56L -35Cr -53.41L -1.44Cr -18Cr -1.39Cr -1.36Cr -59Cr
Net Debt - -
Projected Income Statement - Annual - Senzime AB
Logo Senzime AB
Senzime AB (publ.) is a Sweden-based company engaged in the development, manufacture and marketing of biosensors for measuring metabolites in biological fluids, such as human blood and cell culture substrates for the pharmaceutical and healthcare segments. The Company focuses on the following application areas: medical diagnostic instruments, pharmaceutical industry, chemical processing, and food and beverage processing. As of December 31, 2011, the Company marketed three products, namely SENZ-100G, for continuous analysis of glucose in the fermentation solutions; SENZ-100L, for continuous analysis of lactate in fermentation solutions, and SENZ-200G, for continuous analysis of glucose in blood during intensive care.
Employees
59
Date Price Change Volume
16/26/16 SEK 2.755 +2.80% 1,69,625
15/26/15 SEK 2.680 -3.07% 3,79,064
14/26/14 SEK 2.765 -0.54% 4,59,901
13/26/13 SEK 2.780 -0.71% 8,88,553
12/26/12 SEK 2.800 -4.11% 5,65,028

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Senzime AB
  1. Stock Market
  2. Stocks
  3. SEZI Stock